PolyPeptide Group AG
SIX:PPGN
PolyPeptide Group AG
SIX:PPGN
Price:
24.75
CHF
-0.6%
Market Closed
Market Cap:
CHf820m
Balance Sheet
Balance Sheet Decomposition
PolyPeptide Group AG
PolyPeptide Group AG
Balance Sheet Decomposition is not available for
PolyPeptide Group AG
PolyPeptide Group AG
Balance Sheet
PolyPeptide Group AG
PolyPeptide Group AG
Currency: EUR
| Dec-2018 | Dec-2019 | Dec-2020 | Dec-2021 | Dec-2022 | Dec-2023 | Dec-2024 | Dec-2025 | ||
|---|---|---|---|---|---|---|---|---|---|
| Assets | |||||||||
| Cash & Cash Equivalents |
10
|
18
|
17
|
136
|
38
|
96
|
68
|
75
|
|
| Cash Equivalents |
10
|
18
|
17
|
136
|
38
|
96
|
68
|
75
|
|
| Total Receivables |
51
|
45
|
65
|
76
|
62
|
96
|
107
|
88
|
|
| Accounts Receivables |
42
|
34
|
56
|
68
|
49
|
79
|
86
|
64
|
|
| Other Receivables |
8
|
11
|
10
|
8
|
13
|
17
|
21
|
24
|
|
| Inventory |
72
|
73
|
94
|
113
|
145
|
129
|
146
|
154
|
|
| Other Current Assets |
8
|
7
|
3
|
6
|
7
|
6
|
6
|
8
|
|
| Total Current Assets |
141
|
143
|
180
|
332
|
252
|
327
|
328
|
325
|
|
| PP&E Net |
116
|
137
|
170
|
235
|
297
|
324
|
389
|
459
|
|
| PP&E Gross |
116
|
137
|
170
|
235
|
297
|
324
|
389
|
459
|
|
| Accumulated Depreciation |
116
|
117
|
129
|
135
|
157
|
175
|
205
|
227
|
|
| Intangible Assets |
11
|
12
|
13
|
14
|
16
|
16
|
15
|
14
|
|
| Note Receivable |
0
|
0
|
0
|
0
|
0
|
0
|
2
|
2
|
|
| Long-Term Investments |
3
|
0
|
0
|
3
|
3
|
5
|
5
|
8
|
|
| Other Long-Term Assets |
13
|
13
|
14
|
10
|
8
|
17
|
18
|
19
|
|
| Total Assets |
284
N/A
|
305
+8%
|
376
+23%
|
595
+58%
|
576
-3%
|
689
+20%
|
757
+10%
|
826
+9%
|
|
| Liabilities | |||||||||
| Accounts Payable |
15
|
18
|
28
|
28
|
46
|
61
|
73
|
74
|
|
| Accrued Liabilities |
12
|
10
|
13
|
17
|
12
|
15
|
15
|
16
|
|
| Short-Term Debt |
18
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Current Portion of Long-Term Debt |
6
|
1
|
12
|
4
|
5
|
47
|
37
|
7
|
|
| Other Current Liabilities |
12
|
27
|
48
|
54
|
33
|
54
|
69
|
89
|
|
| Total Current Liabilities |
64
|
56
|
102
|
104
|
96
|
176
|
195
|
187
|
|
| Long-Term Debt |
40
|
34
|
52
|
25
|
27
|
78
|
68
|
134
|
|
| Deferred Income Tax |
2
|
1
|
1
|
1
|
2
|
4
|
3
|
4
|
|
| Other Liabilities |
30
|
64
|
43
|
44
|
29
|
50
|
134
|
160
|
|
| Total Liabilities |
136
N/A
|
156
+14%
|
198
+27%
|
174
-12%
|
154
-11%
|
308
+100%
|
399
+30%
|
485
+22%
|
|
| Equity | |||||||||
| Common Stock |
50
|
33
|
33
|
0
|
0
|
0
|
0
|
0
|
|
| Retained Earnings |
98
|
117
|
148
|
200
|
218
|
166
|
141
|
123
|
|
| Additional Paid In Capital |
2
|
2
|
2
|
213
|
203
|
203
|
203
|
203
|
|
| Treasury Stock |
0
|
0
|
0
|
1
|
14
|
10
|
8
|
6
|
|
| Other Equity |
2
|
3
|
6
|
9
|
14
|
22
|
21
|
21
|
|
| Total Equity |
148
N/A
|
149
+1%
|
178
+19%
|
421
+137%
|
422
+0%
|
381
-10%
|
357
-6%
|
341
-5%
|
|
| Total Liabilities & Equity |
284
N/A
|
305
+8%
|
376
+23%
|
595
+58%
|
576
-3%
|
689
+20%
|
757
+10%
|
826
+9%
|
|
| Shares Outstanding | |||||||||
| Common Shares Outstanding |
33
|
33
|
33
|
33
|
33
|
33
|
33
|
33
|
|
Switch to:
Switch to:
See Also
Discover More
